Cixutumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cixutumumab
Accession Number
DB12250  (DB05759)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.

Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
IMC-A12
Categories
UNII
2285XW22DR
CAS number
947687-12-9

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Cixutumumab is a fully human monoclonal antibody that specifically targets the type 1 human insulin-like growth factor receptor (IGF-IR). Tumors have receptors for the insulin-like growth factor-1 (IGF-I), and it is thought that the presence of these receptors cause tumors to grow. Cixutumumab attaches to the receptors and may inhibit the growth of cancer cells.

TargetActionsOrganism
UInsulin-like growth factor 1 receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

148 h (3 mg/kg dose level) 209 h (6mg/kg dose level)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cixutumumab.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cixutumumab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cixutumumab.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Cixutumumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cixutumumab.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cixutumumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cixutumumab.Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cixutumumab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cixutumumab.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cixutumumab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cixutumumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cixutumumab.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Cixutumumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Cixutumumab.Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cixutumumab.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Cixutumumab.Approved
Food Interactions
Not Available

References

General References
  1. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. [PubMed:17875788]
  2. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9. [PubMed:15757893]
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAdvanced Solid Tumors1
1CompletedTreatmentAdult Angiosarcoma / Adult Desmoplastic Small Round Cell Tumor / Adult Epithelioid Sarcoma / Adult Extraskeletal Myxoid Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Mesenchymoma / Adult Malignant Peripheral Nerve Sheath Tumor / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone / Childhood Angiosarcoma / Childhood Desmoplastic Small Round Cell Tumor / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Malignant Mesenchymoma / Childhood Malignant Peripheral Nerve Sheath Tumor / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Childhood Synovial Sarcoma / Dermatofibrosarcoma Protuberans / Malignant Adult Hemangiopericytoma / Malignant Childhood Hemangiopericytoma / Metastatic Childhood Soft Tissue Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
1CompletedTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentGastrin-Producing Neuroendocrine Tumor / Lung Carcinoid Tumor / Metastatic Digestive System Neuroendocrine Tumor G1 / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Polypeptide Tumor / Paraganglioma / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Merkel Cell Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Somatostatin-Producing Neuroendocrine Tumor / Stage III Merkel Cell Carcinoma / Stage IV Merkel Cell Carcinoma / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentTumors1
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1WithdrawnTreatmentGliomas / Neoplasms, Brain Stem / Pinealoma1
1, 2Active Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2CompletedTreatmentStage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Recurrent Esophageal Carcinoma / Squamous Cell Carcinoma of Esophagus / Stage IV Esophageal Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentChildhood Alveolar Soft-part Sarcoma / Childhood Angiosarcoma / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Gliosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Neurofibrosarcoma / Childhood Synovial Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Osteosarcoma1
2Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Extensive Stage Small Cell Lung Carcinoma / Recurrent Small Cell Lung Cancer / Recurrent Small Cell Lung Carcinoma1
2Active Not RecruitingTreatmentHER2/Neu Positive / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentPeritoneal Mesotheliomas / Pleural Mesotheliomas1
2CompletedTreatmentAdenocarcinoma of the Prostate1
2CompletedTreatmentAdipocytic Sarcoma / Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) / Leiomyosarcomas / Rhabdomyosarcomas / Synovial Sarcoma1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2CompletedTreatmentAdult Rhabdomyosarcoma / Adult Synovial Sarcoma / Childhood Hepatoblastoma / Childhood Synovial Sarcoma / Neuroectodermal Tumors / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adrenocortical Carcinoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Retinoblastoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentCarcinoma NOS / Neuroendocrine Tumors1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Iris Melanoma / Metastatic Intraocular Melanoma / Recurrent Intraocular Melanoma / Stage IV Intraocular Melanoma1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentLeukemia, Mast-Cell1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Osteosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Osteosarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentProstate Cancer2
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentAdenocarcinoma of the Lung / Bronchioloalveolar Carcinoma / Bronchioloalveolar Lung Carcinoma / Large Cell Lung Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRecurrent Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein tyrosine kinase activity
Specific Function
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involv...
Gene Name
IGF1R
Uniprot ID
P08069
Uniprot Name
Insulin-like growth factor 1 receptor
Molecular Weight
154791.73 Da

Drug created on October 20, 2016 15:43 / Updated on June 08, 2017 09:40